Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 16;12:2223–2231. doi: 10.2147/DDDT.S163595

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Huang et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Effect of nimotuzumab or celecoxib on the cell viability of nasopharyngeal carcinoma cells. (A and B) CNE1 and CNE2 cells were treated with various concentrations of celecoxib for 24, 48 and 72 hours. (C and D) CNE1 and CNE2 cells were treated with various concentrations of nimotuzumab for 24, 48 and 72 hours. Cell viability was evaluated by MTT assay. *p < 0.05 vs 0 μmol/L celecoxib at indicated time points. ^Δp < 0.05 vs 24-hour incubation at indicated drug concentrations. ^#p < 0.05 vs 48-hour incubation at indicated drug concentrations.

Abbreviation: MTT, 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide.